Dabigatran is an anticoagulant medication that is used to prevent blood clots and strokes in patients with atrial fibrillation. The drug is sold in the form of 75mg, 110mg, and 150mg dabigatran oral capsules. Dabigatran was developed by the manufacturer and supplier Boehringer Ingelheim. Upon development, dabigatran was the first alternative to warfarin – the conventional anticoagulant therapeutic drug – in over 50 years. It was first approved for medical use by the EMA in 2008, and by the FDA in 2010. Currently, dabigatran has been approved in and supplied to over 100 countries worldwide. And it is also included in the World Health Organization’s list of Essential Medicines that contains the safest and most effective drugs recommended for a health system. Given that the patent for dabigatran is still valid until 2027, there are no generic variants of it available on the global pharmaceutical market, i.e. as of yet Boehringer Ingelheim is the sole manufacturer and supplier of dabigatran medications. That being said, there are other anticoagulant medications used to treat the same indications as dabigatran. Examples include rivaroxaban (marketed by manufacturer Bayer as Xarelto) and apixaban (marketed by manufacturing companies Pfizer and Bristol Meyer’s Squib as Eliquis). Both of these drugs are slightly costlier than dabigatran. There are, however, no definitive head-to-head clinical studies that compare the efficacy of these anticoagulants. An additional alternative is warfarin, which is a far cheaper, albeit a less effective drug than dabigatran, rivaroxaban or apixaban.

A competitive direct thrombin inhibitor (DTI) with a Ki of 4.5 0.2 nmol/L, dabigatran is a meromorphic reversible DTI. Furthermore, some normal physiological thrombin activity is thought to be permitted by the inhibition's reversible nature, which may lessen the side effects of anticoagulant medication. Dabigatran also contains a number of glucuronidated intermediates, all of which have been demonstrated to exhibit in vitro activity comparable to that of the parent drug. Dabigatran has been demonstrated to suppress platelet aggregation, additional step in the coagulation process, in addition to having a direct impact on thrombin activity. Dabigatran suppresses platelet aggregation produced by thrombin and von Willebrand factor (vWF), though not by other pathways like ADP- or thromboxane A2-driven aggregation, therefore the mechanism is still unknown.

The retail price for 30 tablets of dabigatran is approximately 40.00 EUR. Prices of Dabigatran medications differ depending on the active ingredient concentration per tablet, whether it is an immediate-release or extended-release formulation, and whether it is a generic or branded formulation, as well as supplier and manufacturer pricing. Also the costs of Dabigatran vary depending on manufacturer and supplier pricing, whether it is a generic or trade name formulation, concentration of the active ingredient in the formulation. Dabigatran is available for sale from various Dabigatran vendors at multiple costs. Dabigatran suppliers, on the whole, are in favor of patient aid initiatives.

Buyers are advised that online sellers may attempt to market fraudulent versions of the generic drug, whereas Pipeline Pharma, through its pre-auditing and quality control procedures ensures that only verified Dabigatran manufacturers and wholesalers enter our online marketplace, offering you a risk-free B2B pharmaceutical sales platform. PipelinePharma is the most reliable source for this medication. Finding an honest partner in our business is one of the significant challenges. To overcome this challenge and make one's life easier when looking for a direct manufacturer and supplier of Dabigatran, one can go to the Pipelinepharma website, which assists buyers in locating dependable manufacturers and suppliers of Dabigatran.

Being a global B2B pharmaceutical online marketplace, Pipelinepharma is structured to simplify pharmaceutical deals by providing you with an intuitive interface that is easy to engage with. The selection of Dabigatran offerings can be narrowed down with filters and easily weighed against one another according to medication prices and commercial terms. The advanced filters help you filter out the countries for this substance manufacturer and Dabigatran suppliers that you are looking for. These also enable you to check the dossier status of this medicine and the GMP approvals of the different variants of Dabigatran. Also, each manufacturer or supplier product description contains essential information about this substance, including clinical data, stability zones, and countries in which Dabigatran is already registered. Manufacturers also have special delivery terms.

Suppose you are a pharmaceutical licensing company or a distributor. In that case, you can enter into deals or negotiations over these medicine offers with manufacturing companies after completing the free registration process and joining our online marketplace. This helps ensure that you conclude the pharmaceutical deal at a reasonable cost and achieve the best cost/benefit ratio for your company while bypassing lengthy sourcing, negotiation, and order process. Once you have finalized a deal, you can look forward to a long-lasting business relationship with the Dabigatran suppliers. This way, the marketplace allows you as a distributor to skip the process of making a list of product manufacturers every time you are looking for in-licensing or distribution deals.

To keep up to the quality standards other than Good Manufacturing Practice approvals that this medicine manufacturers list has, we qualify their companies before they are boarded on the platform. This allows us to screen Dabigatran manufacturers for the quality of the pharmaceutical products' dossiers and protect against the risk of possible malpractices.